Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 7Ovarian Neoplasms 6Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Urogenital Neoplasms 3Stomach Neoplasms 3Neoplasm Metastasis 3Leukemia, Myeloid, Acute 3Gastrointestinal Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Rectal Neoplasms 2Multiple Myeloma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroblastoma 1Myelodysplastic Syndromes 1

Interventions

fludarabine 4fludarabine phosphate 3asciminib 3venetoclax 2gilteritinib 2Whole-Body Irradiation 2Tacrolimus 2Idarubicin 2Cytarabine 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2ponatinib 1nilotinib 1enasidenib 1blinatumomab 1aldesleukin 1Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Mycophenolic Acid 1Methotrexate 1Mesna 1Melphalan 1Interleukin-2 1Imatinib Mesylate 1Hyperbaric Oxygenation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × aldesleukin × 90 days × Clear all
NCT06152809 2026-03-18

CIML NK Cells With Venetoclax for AML

Dana-Farber Cancer Institute

Phase 1 Recruiting
10 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡